INNEXUS BIOTECHNOLOGY, INC. Inactive Instrument
InNexus Biotechnology, Inc. Stock Other OTC
Equities
IXSBF
CA45771Q1046
Biotechnology & Medical Research
Financials (USD)
| Sales 2009 | - | Sales 2010 | - | Capitalization | 2.89M |
|---|---|---|---|---|---|
| Net income 2009 | -8M | Net income 2010 | -6M | EV / Sales 2009 | - |
| Net Debt 2009 | 3.35M | Net Debt 2010 | 5.64M | EV / Sales 2010 | - |
| P/E ratio 2009 |
-0.92
x | P/E ratio 2010 |
-0.36
x | Employees | - |
| Yield 2009 * |
-
| Yield 2010 |
-
| Free-Float | 92.4% |
More Fundamentals
* Assessed data
More press releases
Innexus Biotechnology Inc is a Canada-based development-stage company. The Company is a drug development company focused on commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. It is engaged in monetizing its technology for its own product development projects whether independently, through collaborations with strategic partners and/or through business development activities for the licensing and sale of its technologies and services. The Company focuses on developing and marketing DXL technology to the biotechnology and pharmaceutical community by launching and developing multiple product candidates. These candidates include potential therapeutic and diagnostic products.
| 1st Jan change | Capi. | |
|---|---|---|
| -0.49% | 105B | |
| +3.31% | 97.5B | |
| +3.09% | 22.19B | |
| -16.16% | 21.33B | |
| -7.19% | 18.68B | |
| -41.41% | 16.6B | |
| -22.87% | 14.52B | |
| +6.32% | 14.09B | |
| +21.46% | 10.99B |
